2025-11-03T18:04:01-06:00 2025-06-30 991856619 GRANT THORNTON ADVISORS LLC 1000 WILSON BOULEVARD SUITE 1500 ARLINGTON VA 22209 990 2024-07-01 237135845 THE FOUNDATION FIGHTING BLINDNESS INC FOUN 4104230600 6925 OAKLAND MILLS ROAD 701 COLUMBIA MD 21045 PETER GINSBERG CHIEF OPERATING OFFICER 4104230600 2025-11-03 1 1 MARY TORRETTA P00847851 7038477500 2024 2025-03-06 01:10:19Z JASON D MENZO 6925 OAKLAND MILLS ROAD 701 COLUMBIA MD 21045 70836638 0 X WWW.FIGHTINGBLINDNESS.ORG X 1971 MD SEE SCHEDULE O 25 24 96 2500 0 0 31823323 31063702 1028762 2004208 1323599 2544692 1526874 1002567 35702558 36615169 21112113 22880201 0 0 10515059 11708364 542609 732305 9011999 16056630 14211512 48226411 49532382 -12523853 -12917213 124009134 110885645 31398627 27016811 92610507 83868834 X TO DRIVE THE RESEARCH THAT WILL PROVIDE PREVENTIONS, TREATMENTS AND CURES, FOR PEOPLE AFFECTED BY RETINITIS PIGMENTOSA, MACULAR DEGENERATION, USHER SYNDROME, AND THE SPECTRUM OF RETINAL DEGENERATIVE DISEASES. 0 0 32043327 22880201 2004208 SEE SCHEDULE O 3681241 SEE SCHEDULE O 1641058 SEE SCHEDULE O 37365626 1 1 0 1 0 0 0 0 0 1 1 0 0 1 1 1 0 1 0 0 1 1 0 1 1 0 0 1 0 1 0 0 0 0 0 0 0 0 1 0 0 0 0 1 1 1 0 0 1 208 0 1 96 1 0 0 0 0 0 1 1 0 0 0 0 0 0 X 25 24 1 0 1 0 1 1 0 1 1 0 0 1 1 1 1 1 1 1 1 0 AL AK AR CA CO CT FL GA HI KS IL IN MA ME MD MI MN MS NH NJ NY NC OH OK OR PA SC TN UT VA WA WV WI AZ X X PETER GINSBERG 4104230600 6925 OAKLAND MILLS ROAD 701 COLUMBIA MD 21045 X ADRIENNE GRAVES PHD DIRECTOR 1.00 1.00 X 0 12500 0 KAREN PETROU BOARD CHAIR 10.00 1.00 X X 0 0 0 JASON MORRIS EXECUTIVE VICE CHAIR 1.00 0.00 X X 0 0 0 HAYNES LEA BOARD SECRETARY 1.00 0.00 X X 0 0 0 STEVEN ALPER CHAIR, DEVELOPMENT 1.00 0.00 X X 0 0 0 JEFFREY FREED CHAIR, AUDIT & RISK 1.00 0.00 X X 0 0 0 DAVID NIXON CHAIR, FINANCE & INVESTMENT; TREAS. 1.00 0.00 X X 0 0 0 JONATHAN STEINBERG MD CHAIR, SCIENCE 1.00 1.00 X X 0 0 0 MARYROSE SYLVESTER CHAIR, AT LARGE 1.00 0.00 X X 0 0 0 WARREN THALER CHAIR, NOMINATING & GOVERNANCE 1.00 1.00 X X 0 0 0 GORDON GUND DIRECTOR - CHAIRMAN EMERITUS 1.00 0.00 X X 0 0 0 DAVID BRINT DIRECTOR 1.00 0.00 X 0 0 0 SCOTT BURT DIRECTOR 1.00 0.00 X 0 0 0 DARREN DEVOUE DIRECTOR 1.00 0.00 X 0 0 0 LAURA FIETTA DIRECTOR 1.00 0.00 X 0 0 0 ROBERT HEIDENBERG DIRECTOR 1.00 0.00 X 0 0 0 SUBER HUANG MD DIRECTOR 1.00 0.00 X 0 0 0 MARSHA LINK PHD DIRECTOR 1.00 0.00 X 0 0 0 LAURA MANFRE DIRECTOR 1.00 0.00 X 0 0 0 BRADFORD MANNING DIRECTOR 1.00 0.00 X 0 0 0 JANINE MARKS NIXON DIRECTOR 1.00 0.00 X 0 0 0 EVAN MITTMAN DIRECTOR 1.00 0.00 X 0 0 0 GEORGE PEINADO DIRECTOR 1.00 0.00 X 0 0 0 MARTHA STEELE DIRECTOR 1.00 0.00 X 0 0 0 JOSHUA STEINBERG DIRECTOR 1.00 0.00 X 0 0 0 JASON D MENZO CEO 32.00 8.00 X 504560 126140 93231 PETER L GINSBERG COO 32.00 8.00 X 364025 91006 85311 AMY M PALMER LASTER CHIEF SCIENTIFIC OFFICER 40.00 0.00 X 281622 0 27061 RUSSELL W KELLEY MANAGING DIRECTOR, RD FUND 0.00 40.00 X 0 447300 85994 TODD A DURHAM SVP CLINICAL & OUTCOMES RESEARCH 40.00 0.00 X 324179 0 80261 JEFFREY D KLAAS CHIEF OF STRATEGY AND INNOVATION 40.00 0.00 X 344934 0 33516 RICHELE DONAT CHIEF HUMAN RESOURCES OFFICER 40.00 0.00 X 324700 0 45263 JUDY TAYLOR SVP/CHIEF DEVELOPMENT OFFICER 40.00 0.00 X 290836 0 74299 CHRISTOPHER S ADAMS VP, COMMUNICATIONS & MARKETING 40.00 0.00 X 237414 0 64234 MICHELE DIVINCENZO VP, SCIENTIFIC & ED. CONFERENCES 40.00 0.00 X 239787 0 60971 JEFFRY COLLINS VP, DATABASE SYSTEMS & TECHNOLOGY 40.00 0.00 X 234136 0 53880 ANNA WAGNER VP, FINANCE 40.00 0.00 X 239697 0 22111 CHAD R JACKSON - SR DIR PRE-CLINICAL TRANSITIONAL PROG. 40.00 0.00 X 207565 0 17439 CLAIRE M GELFMAN FORMER CSO (THRU 6/24) 40.00 0.00 X 341844 0 31176 3935299 676946 774747 31 1 1 0 FUSE FUNDRAISING GROUP LLC 12355 SUNRISE VALLEY DRIVE SUITE 2 RESTON VA 20191 DIRECT MARKETING CONSULTANT 627860 CHICAGO DOWNTOWN MARRIOTT 540 N MICHIGAN AVENUE CHICAGO IL 60611 VENUE FOR VISIONS 2024 298482 FAIRMONT SCOTTSDALE PRINCESS 7575 EAST PRINCESS DRIVE SCOTTSDALE AZ 85255 VENUE FOR ICS 2024 287477 HORIZON GOVERNMENT 440 1ST ST NW SUITE 430 WASHINGTON DC 20001 GOVERNMENT RELATIONS CONSULTANT 240000 MOLECULAR MEDIA INC 8670 66TH COURT PINELLAS PARK FL 33782 AV EQUIPMENT RENTAL 218718 12 83597 6254537 167647 24557921 846278 31063702 CONTRACT REVENUE 900099 1889982 1889982 PROGRAM FEES 900099 114226 114226 2004208 3256434 3256434 1407035 1407035 35179 0 35179 35179 35179 32465155 33176897 -711742 -711742 -711742 604925 6254537 1044572 -439647 -439647 36615169 2004208 0 3547259 19306746 19306746 3573455 3573455 2416444 904110 602750 909584 6983907 2597079 871881 3514947 417135 161154 68373 187608 1215324 459160 115915 640249 675554 249925 103530 322099 2247246 1051166 304111 891969 54745 1620 53125 58255 52880 5375 240000 240000 732305 732305 183052 156583 26469 493157 322722 10343 160092 543281 121487 76822 344972 396738 31008 87625 278105 127012 18234 69888 38890 483233 146710 80127 256396 1123066 482590 272298 368178 105654 88591 500 16563 208608 123024 24364 61220 RESEARCH TRIAL COSTS 7335750 7335750 PRINTING & PRODUCTION 325348 150097 23865 151386 286367 998 179777 105592 49532382 37365626 3154757 9011999 5907841 2694746 5399724 6101316 16206701 9572815 553927 1390576 16732 6943 683433 828606 4121573 3521005 691222 600568 85735053 80569953 8814501 9120122 124009134 110885645 2799115 2235740 21184147 18542798 550960 861444 6864405 5376829 31398627 27016811 X 20614062 20367885 71996445 63500949 92610507 83868834 124009134 110885645 X -12917213 4163847 11693 X 0 1 X 1 0 X 27741201 39734129 28901504 31823323 31063702 159263859 27741201 39734129 28901504 31823323 31063702 159263859 29887457 129376402 4394213 4142169 3519873 5031481 4698648 21786384 130714 1099664 919337 891321 604925 3645961 184696204 4255050 0.70050 0.63210 X SCHEDULE A, PART II, LINE 10, EXPLANATION OF OTHER INCOME: FFB RD FUND SERVICE FEES - 2020 AMOUNT: $ 30,500. FUNDRAISING EVENTS - 2020 AMOUNT: $ 100,200. 2021 AMOUNT: $ 349,599. 2022 AMOUNT: $ 919,261. 2023 AMOUNT: $ 891,321. 2024 AMOUNT: $ 604,925. SETTLEMENT INCOME - 2021 AMOUNT: $ 750,000. MISCELLANEOUS - 2020 AMOUNT: $ 14. 2021 AMOUNT: $ 65. 2022 AMOUNT: $ 76. RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 240000 240000 40280383 40520383 1000000 250000 0 0 1000000 1000000 1000000 3000000 4500000 260000 240000 240000 740000 250000 250000 250000 750000 1125000 4593101 622389 5215490 4033188 559913 4593101 3634618 398570 4033188 4200522 -565904 3634618 3422374 939020 145067 15805 4200522 1.00000 0 0 504643 414879 89764 3616930 3106126 510804 600568 BENEFICIAL INTERESTS IN REMAINDER TRUSTS 8381381 CHARITABLE GIFT ANNUITY 738741 9120122 DUE TO RELATED PARTY 4881016 CHARITABLE GIFT ANNUITY OBLIGATION 495813 5376829 X 40711236 4163847 88803 4252650 36458586 156583 156583 36615169 49452909 88803 -11693 77110 49375799 156583 156583 49532382 PART V, LINE 4: EARNINGS CAN BE USED FOR OPERATIONS; PRINCIPAL IS DONOR RESTRICTED. PART X, LINE 2: THE ORGANIZATION FOLLOWS THE ACCOUNTING STANDARD ON ACCOUNTING FOR UNCERTAINTY IN INCOME TAXES, WHICH ADDRESSES THE DETERMINATION OF WHETHER TAX BENEFITS CLAIMED OR EXPECTED TO BE CLAIMED ON A TAX RETURN SHOULD BE RECORDED IN THE CONSOLIDATED FINANCIAL STATEMENTS. UNDER THIS POLICY, THE ORGANIZATION MAY RECOGNIZE THE TAX BENEFIT FROM AN UNCERTAIN TAX POSITION ONLY IF IT IS MORE LIKELY THAN NOT THAT THE TAX POSITION WOULD BE SUSTAINED ON EXAMINATION BY TAXING AUTHORITIES, BASED ON THE TECHNICAL MERITS OF THE POSITION. MANAGEMENT HAS EVALUATED THE ORGANIZATION'S TAX POSITIONS AND HAS CONCLUDED THAT THE ORGANIZATION HAS TAKEN NO UNCERTAIN TAX POSITIONS THAT REQUIRE ADJUSTMENT TO THE CONSOLIDATED FINANCIAL STATEMENTS TO COMPLY WITH PROVISIONS OF THIS GUIDANCE. PART XII, LINE 2D - OTHER ADJUSTMENTS: REFUND OF PREVIOUSLY EXPENDED GRANTS -11,693. 1 EUROPE (INCLUDING ICELAND & GREENLAND) 0 0 GRANTMAKING 2583044 MIDDLE EAST AND NORTH AFRICA 0 0 GRANTMAKING 501880 NORTH AMERICA 0 0 GRANTMAKING 488531 EUROPE (INCLUDING ICELAND & GREENLAND) 0 0 PROGRAM SERVICES TRAVEL 38737 0 0 0 0 0 0 3612192 0 3612192 EUROPE (INCLUDING ICELAND & GREENLAND) RESEARCH GRANT 594737 WIRE 0 EUROPE (INCLUDING ICELAND & GREENLAND) RESEARCH GRANT 563080 WIRE 0 MIDDLE EAST AND NORTH AFRICA RESEARCH GRANT 501880 WIRE 0 EUROPE (INCLUDING ICELAND & GREENLAND) RESEARCH GRANT 446000 WIRE 0 EUROPE (INCLUDING ICELAND & GREENLAND) RESEARCH GRANT 300000 WIRE 0 EUROPE (INCLUDING ICELAND & GREENLAND) RESEARCH GRANT 229309 WIRE 0 NORTH AMERICA RESEARCH GRANT 220650 WIRE 0 NORTH AMERICA RESEARCH GRANT 192881 WIRE 0 EUROPE (INCLUDING ICELAND & GREENLAND) RESEARCH GRANT 188553 WIRE 0 EUROPE (INCLUDING ICELAND & GREENLAND) RESEARCH GRANT 99850 WIRE 0 EUROPE (INCLUDING ICELAND & GREENLAND) RESEARCH GRANT 98440 WIRE 0 NORTH AMERICA RESEARCH GRANT 75000 WIRE 0 EUROPE (INCLUDING ICELAND & GREENLAND) RESEARCH GRANT 63075 WIRE 0 13 0 0 0 0 0 0 0 SCHEDULE F, PART I, LINE 2: EACH GRANTEE IS REQUIRED TO SUBMIT A YEARLY SCIENTIFIC PROGRESS REPORT, WHICH IS REVIEWED BY THE FFB SCIENCE STAFF AND COMPARED WITH THE PROPOSED MILESTONES SUBMITTED WITH THE ORIGINAL GRANT APPLICATION. ATTENTION IS ALSO GIVEN TO THE PLAN FOR EXPERIMENTS TO BE PERFORMED IN THE COMING YEAR. ANY PROBLEMS OR ISSUES IDENTIFIED BY THE GRANTEE AND/OR FFB SCIENTIFIC STAFF ARE RESOLVED TO OUR MUTUAL SATISFACTION; HOWEVER, IF A CONSENSUS CANNOT BE REACHED OR IF THE APPARENT PROGRESS IS NOT SATISFACTORY IN THE OPINION OF FFB SCIENTIFIC STAFF, AFTER CONSULTATION WITH MEMBERS OF THE FFB SCIENTIFIC ADVISORY BOARD, THE GRANT IS TERMINATED WITH A SHORT PHASE OUT PERIOD. EACH GRANTEE IS REQUIRED TO SUBMIT A YEARLY FINANCIAL REPORT DETAILING GRANT EXPENDITURES ACCORDING TO THEIR FFB APPROVED GRANT BUDGET. SCIENCE STAFF REVIEW EACH FINANCIAL REPORT FOR ADHERENCE TO BUDGETED EXPENDITURES IN EACH CATEGORY. WITH PROPER DOCUMENTATION AND IF DETERMINED APPROPRIATE, REQUESTS FOR CARRYOVER OF UNEXPENDED FUNDS TO THE NEXT FISCAL YEAR ARE REVIEWED AND APPROVED ON A CASE-BY-CASE BASIS. X X X X X X X 1 FUSE FUNDRAISING GROUP LLC 12355 SUNRISE VALLEY DRIVE SUITE 2 RESTON VA 20191 FUNDRAISING COUNSEL 0 1074000 457304 616696 COMMUNITY COUNSELING SERVICE LLC 527 MADISON AVE 5TH FL NEW YORK NY 10022 FUNDRAISING CAMPAIGN COUNSEL 0 0 275001 -275001 1074000 732305 341695 AL AK AZ AR CA CO CT DE FL GA HI ID IL IN IA KS KY LA ME MD MA MI MN MS MO MT NE NV NH NJ NM NY NC ND OH OK OR PA RI SC SD TN TX UT VT VA WA WV WI WY NIGHT SIGHT NY 483177 358977 124200 138432 10500 5683 GIFT OF VISION 410703 373803 36900 3742 32006 7395 42957 48 5965582 5521757 443825 425029 148128 7030 223670 6859462 6254537 604925 567203 180134 24925 272310 1044572 -439647 1 CASE WESTERN RESERVE UNIVERSITY 10900 EUCLID AVENUE CLEVELAND OH 44106 341018992 501(C)(3) 500000 0 RESEARCH COLUMBIA UNIVERSITY 635 WEST 165TH STREET NEW YORK NY 10032 135598093 501(C)(3) 200000 0 RESEARCH DUKE UNIVERSITY MEDICAL CENTER 2200 W MAINE STREET DURHAM NC 27705 560532129 501(C)(3) 900000 0 RESEARCH FORDHAM UNIVERITY 441 FORDHAM ROAD BRONX NY 10458 131740451 501(C)(3) 539141 0 RESEARCH FOUNDATION FIGHTING BLINDNESS RD FUND 6925 OAKLAND MILLS ROAD 701 COLUMBIA MD 21045 450524687 501(C)(3) 8771404 0 RESEARCH FOUNDATION FOR THE NIH 11400 ROCKVILLE PIKE SUITE 600 NORTH BETHESDA MD 20852 521986675 501(C)(3) 25000 0 RESEARCH HARVARD MEDICAL SCHOOL 220 LONGWOOD AVENUE BOSTON MA 02114 042103580 501(C)(3) 402223 0 RESEARCH INDIANA UNIVERSITY 509 E 3RD STREET BLOOMINGTON IN 47405 356001673 501(C)(3) 169257 0 RESEARCH JOHNS HOPKINS UNIVERSITY 600 NORTH WOLFE STREET BALTIMORE MD 21287 520595110 501(C)(3) 166454 0 RESEARCH MASSACHUSETTS EYE AND EAR INFIRMARY 243 CHARLES STREET BOSTON MA 02114 042103591 501(C)(3) 396667 0 RESEARCH MEDICAL COLLEGE OF WISCONSIN 8701 WATERTOWN PLANK ROAD MILWAUKEE WI 53226 390806261 501(C)(3) 100000 0 RESEARCH MICHIGAN STATE UNIVERSITY 736 WILSON ROAD D208 EAST LANSING MI 48823 386005984 501(C)(3) 267406 0 RESEARCH MITOCHEM THERAPEUTICS INC 17C FRANKLIN STREET CHARLESTON SC 29401 453845208 300000 0 RESEARCH NEW YORK STEM CELL FOUNDATION 619WEST 54TH STREET 3RD FLOOR NEW YORK NY 10019 202905531 501(C)(3) 296150 0 RESEARCH OAKLAND UNIVERSITY 371 WILSON BLVD ROCHESTER MI 48309 381714400 501(C)(3) 140255 0 RESEARCH ODYLIA THERAPEUTICS 1447 PEACHTREE STREET NE ATLANTA GA 30309 822120760 501(C)(3) 631039 0 RESEARCH OHIO STATE UNIVERSITY 1960 KENNY ROAD COLUMBUS OH 43210 316025986 501(C)(3) 75000 0 RESEARCH OREGON HEALTH AND SCIENCE UNIVERSITY 3375 TERWILLIGER BOULEVARD SW PORTLAND OR 97201 237083114 501(C)(3) 460869 0 RESEARCH RETINA FOUNDATION OF THE SOUTHWEST 9600 N CENTRAL EXPRESSWAY SUITE 200 DALLAS TX 75231 510151514 501(C)(3) 100000 0 RESEARCH TUFTS UNIVERSITY 136 HARRISON AVENUE BOSTON MA 02155 042103634 501(C)(3) 199999 0 RESEARCH UNIV ALABAMA AT BIRMINGHAM 1670 UNIVERSITY BLVD BIRMINGHAM AL 35293 636005396 501(C)(3) 100000 0 RESEARCH UNIVERSITY HOSPITALS UH GRANTS DEPT 781686 PO BOX 78000 DETROIT MI 48278 341567805 501(C)(3) 178641 0 RESEARCH UNIVERSITY OF CALIFORNIA DAVIS HEALTH 944 GARROD DRIVE DAVIS CA 95616 464117124 501(C)(3) 200000 0 RESEARCH UNIVERSITY OF CALIFORNIA SAN DIEGO 9500 GILMAN DRIVE LA JOLLA CA 92037 956006144 501(C)(3) 75000 0 RESEARCH UNIVERSITY OF CALIFORNIA IRVINE 228 ALDRICH HALL IRVINE CA 92697 952226406 501(C)(3) 914667 0 RESEARCH UNIVERSITY OF CALIFORNIA SANTA BARBARA 3102 SAASB ROAD SANTA BARBARA CA 93106 956006145 501(C)(3) 300000 0 RESEARCH UNIVERSITY OF DELAWARE 590 AVENUE 1743 NEWARK DE 19716 911955015 501(C)(3) 100000 0 RESEARCH UNIVERSITY OF FLORIDA PO BOX 100284 GAINESVILLE FL 32610 592729133 501(C)(3) 24565 0 RESEARCH UNIVERSITY OF HOUSTON 3517 CULLEN BLVD HOUSTON TX 77204 746001399 501(C)(3) 160400 0 RESEARCH UNIVERSITY OF ILLINOIS-CHICAGO 1855 WEST TAYLOR STREET CHICAGO IL 60612 376000511 501(C)(3) 75000 0 RESEARCH UNIVERSITY OF MICHIGAN 733 KELLOGG EYE CENTER 1000 WALL STREET ANN ARBOR MI 48105 386006309 501(C)(3) 250000 0 RESEARCH UNIVERSITY OF MISSOURI 920 EAST CAMPUS LAN S105C ASRC COLUMBIA MO 65211 436003859 501(C)(3) 119955 0 RESEARCH UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE 120 MASON FARM ROAD CHAPEL HILL NC 27599 566001393 501(C)(3) 50000 0 RESEARCH UNIVERSITY OF PENNSYLVANIA 3451 WALNUT STREET PHILADELPHIA PA 19104 232810852 501(C)(3) 1398985 0 RESEARCH UNIVERSITY OF PITTSBURGH 123 UNIVERSITY PLACE PITTSBURGH PA 15213 250965591 501(C)(3) 375000 0 RESEARCH UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON 7000 FANNIN UCT 1000 HOUSTON TX 77030 741761309 501(C)(3) 24998 0 RESEARCH UNIVERSITY OF WASHINGTON 1100 45TH ST NE SEATTLE WA 98105 943079432 501(C)(3) 474235 0 RESEARCH UNIVERSITY OF WISCONSIN 21 NORTH PARK STREET MADISON WI 53715 390743975 501(C)(3) 200000 0 RESEARCH 37 1 PART I, LINE 2: EACH GRANTEE IS REQUIRED TO SUBMIT A YEARLY SCIENTIFIC PROGRESS REPORT, WHICH IS REVIEWED BY THE FFB SCIENCE STAFF AND COMPARED WITH THE PROPOSED MILESTONES SUBMITTED WITH THE ORIGINAL GRANT APPLICATION. ATTENTION IS ALSO GIVEN TO THE PLAN FOR EXPERIMENTS TO BE PERFORMED IN THE COMING YEAR. ANY PROBLEMS OR ISSUES IDENTIFIED BY THE GRANTEE AND/OR FFB SCIENTIFIC STAFF ARE RESOLVED TO OUR MUTUAL SATISFACTION; HOWEVER, IF A CONSENSUS CANNOT BE REACHED OR IF THE APPARENT PROGRESS IS NOT SATISFACTORY IN THE OPINION OF FFB SCIENTIFIC STAFF, AFTER CONSULTATION WITH MEMBERS OF THE FFB SCIENTIFIC ADVISORY BOARD, THE GRANT IS TERMINATED WITH A SHORT PHASE OUT PERIOD. EACH GRANTEE IS REQUIRED TO SUBMIT A YEARLY FINANCIAL REPORT DETAILING GRANT EXPENDITURES ACCORDING TO THEIR FFB APPROVED GRANT BUDGET. SCIENCE STAFF REVIEW EACH FINANCIAL REPORT FOR ADHERENCE TO BUDGETED EXPENDITURES IN EACH CATEGORY. WITH PROPER DOCUMENTATION AND IF DETERMINED APPROPRIATE, REQUESTS FOR CARRYOVER OF UNEXPENDED FUNDS TO THE NEXT FISCAL YEAR ARE REVIEWED AND APPROVED ON A CASE-BY-CASE BASIS. X 1 1 X X X X X 1 1 0 0 0 0 0 1 0 JASON D MENZO CEO 352711 88178 78580 19645 73270 18317 28430 7107 46155 11539 579145 144786 0 0 PETER L GINSBERG COO 263793 65948 35664 8916 64569 16142 27635 6909 40614 10153 432274 108068 0 0 RUSSELL W KELLEY MANAGING DIRECTOR, RD FUND 0 326079 0 42765 0 78456 0 32428 0 53566 0 533294 0 0 TODD A DURHAM SVP CLINICAL & OUTCOMES RESEARCH 248037 0 22742 0 53400 0 27692 0 52569 0 404439 0 0 0 JEFFREY D KLAAS CHIEF OF STRATEGY AND INNOVATION 319177 0 25205 0 552 0 29681 0 3834 0 378450 0 0 0 CLAIRE M GELFMAN FORMER CSO (THRU 6/24) 197419 0 47837 0 96587 0 5399 0 25778 0 373020 0 0 0 RICHELE DONAT CHIEF HUMAN RESOURCES OFFICER 241332 0 36336 0 47032 0 24982 0 20281 0 369964 0 0 0 JUDY TAYLOR SVP/CHIEF DEVELOPMENT OFFICER 225276 0 19713 0 45848 0 21949 0 52351 0 365136 0 0 0 AMY M PALMER LASTER CHIEF SCIENTIFIC OFFICER 220154 0 19052 0 42416 0 22422 0 4640 0 308683 0 0 0 CHRISTOPHER S ADAMS VP, COMMUNICATIONS & MARKETING 180257 0 17047 0 40110 0 9013 0 55221 0 301648 0 0 0 MICHELE DIVINCENZO VP, SCIENTIFIC & ED. CONFERENCES 183567 0 16865 0 39355 0 21313 0 39657 0 300758 0 0 0 JEFFRY COLLINS VP, DATABASE SYSTEMS & TECHNOLOGY 178394 0 16316 0 39427 0 20656 0 33224 0 288016 0 0 0 ANNA WAGNER VP, FINANCE 192892 0 15982 0 30823 0 19034 0 3077 0 261808 0 0 0 CHAD R JACKSON - SR DIR PRE-CLINICAL TRANSITIONAL PROG. 183086 0 24318 0 161 0 11064 0 6375 0 225004 0 0 0 PART I, LINE 1A SPOT BONUSES FOR EXTRAORDINARY WORK MIGHT BE PROVIDED TO EMPLOYEES AND ARE GROSSED UP. THESE SPOT BONUSES AND GROSS UPS ARE INCLUDED IN TAXABLE COMPENSATION. PART I, LINES 4A-B SCHEDULE J, PART I, LINE 4A: SEVERANCE PAYMENT IN CALENDAR YEAR 2024, CLAIRE GELFMAN RECEIVED A SEVERANCE PAYMENT OF $20,000 WHICH IS REPORTED AS TAXABLE INCOME ON SCHEDULE J, PART II, COLUMN (B)(III). SCHEDULE J, PART I, LINE 4B: SUPPLEMENTAL NONQUALIFIED RETIREMENT PLAN FFB OFFERS A LONG-TERM INCENTIVE PLAN (LTIP) TO CERTAIN MEMBERS OF THE EXECUTIVE MANAGEMENT TEAM. THE PLAN OPERATES ON A THREE-YEAR CYCLE WHEREIN INCENTIVE PAYMENTS ARE ACCRUED ANNUALLY BASED UPON ACHIEVEMENT OF PERFORMANCE OBJECTIVES AND PAID OUT AT THE END OF THE THREE-YEAR PERIOD. THE LAST CYCLE COVERED FISCAL YEARS 2022, 2023, AND 2024, AND WAS PAID OUT IN THE FALL OF 2024. SUBSEQUENTLY, THE FOLLOWING AMOUNTS ARE INCLUDED AS TAXABLE COMPENSATION IN SCHEDULE J, PART II, COLUMN (B)(III): - JASON D. MENZO: $91,227 - PETER L. GINSBERG: $79,679 - CLAIRE M. GELFMAN: $75,729 - AMY M. PALMER LASTER: $41,945 - RUSSELL W. KELLEY: $77,904 - TODD A. DURHAM: $52,848 - RICHELE DONAT: $46,038 - JUDY TAYLOR: $44,388 - CHRISTOPHER S. ADAMS: $39,717 - MICHELE DIVINCENZO: $38,625 - JEFFRY COLLINS: $38,358 - ANNA WAGNER: $30,670 A NEW LTIP THREE-YEAR CYCLE COMMENCED JULY 1, 2024, AND WILL COVER FISCAL YEARS 2025, 2026, AND 2027. THE FOLLOWING AMOUNTS WERE ACCRUED IN CALENDAR YEAR 2024 AND ARE THEREFORE INCLUDED AS DEFERRED COMPENSATION IN SCHEDULE J, PART II, COLUMN (C): - JASON D. MENZO: $15,531 - PETER L. GINSBERG: $11,589 - AMY M. PALMER LASTER: $7,956 - RUSSELL W. KELLEY: $11,367 - JEFFREY D. KLAAS: $10,707 - TODD A. DURHAM: $8,704 - RICHELE DONAT: $8,265 - JUDY TAYLOR: $7,848 - CHRISTOPHER S. ADAMS: $6,521 - MICHELE DIVINCENZO: $6,485 - JEFFRY COLLINS: $6,264 - ANNA WAGNER: $6,526 PART I, LINE 7 FFB EMPLOYEES PARTICIPATE IN AN ANNUAL INCENTIVE PLAN (AIP). THE PLAN PROVIDES AN ANNUAL CASH BONUS, DEPENDING UPON THE ACHIEVEMENT OF PRE-DETERMINED ORGANIZATION AND INDIVIDUAL PERFORMANCE CRITERIA. CERTAIN SENIOR LEADERSHIP EMPLOYEES PARTICIPATE IN A LONG-TERM INCENTIVE PLAN (LTIP), WHICH PROVIDES A CASH BONUS EVERY THREE YEARS. ELIGIBILITY FOR THE BONUS IS CONTINGENT UPON CONTINUED EMPLOYMENT AND THE ATTAINMENT OF SPECIFIC ORGANIZATIONAL PERFORMANCE GOALS ESTABLISHED IN ADVANCE. BOTH AIP AND LTIP PAYMENTS ARE APPROVED BY THE EXECUTIVE COMMITTEE. X 45 657342 FAIR MARKET VALUE X EVENT ITEMS 631 188936 FAIR MARKET VALUE 0 1 0 PART I, COLUMN (B): THE NUMBER IN THIS COLUMN FOR LINE 9 REPRESENTS THE NUMBER OF CONTRIBUTIONS OF STOCK. PART I, LINE 1, ORGANIZATION'S MISSION OR SIGNIFICANT ACTIVITIES: THE URGENT MISSION OF THE FOUNDATION FIGHTING BLINDNESS IS TO DRIVE THE RESEARCH THAT WILL PROVIDE PREVENTIONS, TREATMENTS AND CURES FOR PEOPLE AFFECTED BY RETINITIS PIGMENTOSA, AGE-RELATED MACULAR DEGENERATION, USHER SYNDROME AND THE ENTIRE SPECTRUM OF RETINAL DEGENERATIVE DISEASES. THE FOUNDATION IS A BEACON FOR THOSE AFFECTED BY THESE BLINDING DISEASES. FORM 990, PART III, LINE 4A RESEARCH: THE FOUNDATION FIGHTING BLINDNESS, INC. (THE FOUNDATION) FUNDED RESEARCHERS ARE ACHIEVING REMARKABLE SUCCESS IN DISCOVERING, TESTING, AND DELIVERING TO PATIENTS A WIDE RANGE OF PROMISING THERAPIES TO PREVENT, STOP THE PROGRESSION OF, AND CURE BLINDING DISEASES DUE TO RETINAL DEGENERATIVE DISEASES. THE FOUNDATION HAS ENCUMBRANCES OF OVER $36 MILLION, NOT INCLUDED ON OUR JUNE 30 FINANCIAL REPORT, FOR ACTIVE RESEARCH PROJECTS THAT HAVE FUTURE RESEARCH MILESTONES. OUR SCIENCE COMMITTEE'S SPENDING PLAN INCLUDES SPENDING AT AN AVERAGE OF $28 MILLION ANNUALLY TO SUPPORT FUTURE RESEARCH. AS OF THE END OF OUR FISCAL YEAR 2025, THE FOUNDATION'S RESEARCH GRANTS PROGRAM IS FUNDING 104 GRANTS BEING CONDUCTED BY MORE THAN 133 INVESTIGATORS AT 92 INSTITUTIONS, EYE HOSPITALS, AND UNIVERSITIES IN THE U.S. AND AROUND THE WORLD. A SAMPLING OF THE RESEARCH PROJECTS FUNDED ARE LISTED BELOW: "DEFINING THE UNDERLYING CAUSES OF RETINAL DEGENERATION IN CRB1 DISEASE." JEREMY KAY, DUKE UNIVERSITY DR. KAY AND HIS TEAM HYPOTHESIZE THAT LOSS OF CELL-CELL CONNECTIONS IN THE OUTER RETINA UNDERLIES RP-LIKE ASPECTS OF CRB1-ASSOCIATED DISEASE, WHILE LOSS OF JUNCTIONS BETWEEN EMBRYONIC PROGENITORS UNDERLIES LCA-LIKE ASPECTS. DR. KAY'S TEAM WILL USE MULTIPLE MODELS TO IDENTIFY PRIMARY SITE(S) OF DAMAGE CAUSED BY CRB1 DYSFUNCTION, AND EXPLORE STRATEGIES TO FIX THE DAMAGE. THEY WILL ALSO WORK TO DETERMINE WHETHER THESE CELLULAR FEATURES CAN BE IMAGED IN ANIMALS AND IN PATIENTS AND BE USED AS AN ENDPOINT IN FUTURE CLINICAL TRIALS. "DEVELOPMENT OF A NEW GENE THERAPY FOR AUTOSOMAL DOMINANT RETINITIS PIGMENTOSA" DENISE MONTELL, UNIVERSITY OF CALIFORNIA, SANTA BARBARA DR. MONTELL IS PIONEERING A GENE THERAPY APPROACH TO COMBAT RETINITIS PIGMENTOSA (RP), SPECIFICALLY THE AUTOSOMAL DOMINANT FORM CAUSED BY MISFOLDED RHODOPSIN PROTEIN. BY PROMOTING THE DEGRADATION OF MISFOLDED RHODOPSIN, THROUGH OVEREXPRESSION OF THE ZIP7 GENE, DR. MONTELL AIMS TO SLOW RETINAL DEGENERATION. ADDITIONALLY, OVEREXPRESSING THE ZIP7 GENEA ZINC TRANSPORTER PROTEINMAY RELIEVE CELLULAR STRESS AND PREVENT PHOTORECEPTOR CELL DEATH IN VARIOUS MODELS OF AUTOSOMAL DOMINANT RP. "CHARACTERIZATION AND MITIGATION OF AAV-INDUCED OCULAR INFLAMMATION" WILLIAM BELTRAN, UNIVERSITY OF PENNSYLVANIA DR. BELTRAN AND HIS TEAM ARE WORKING TO IMPROVE THE SAFETY OF GENE THERAPIES THAT USE VIRAL VECTORS TO DELIVER THE THERAPEUTIC GENE TO RETINAL CELLS. AS MORE IRD GENE THERAPIES MOVE FROM THE PRECLINICAL STAGE IN ANIMAL MODELS TO CLINICAL TRIALS, THERE IS AN INCREASING RECOGNITION OF THE NEED TO BETTER UNDERSTAND GENE THERAPY-ASSOCIATED UVEITIS (INFLAMMATION). THIS INFLAMMATORY RESPONSE CAN IMPEDE THE THERAPY'S PERFORMANCE AND CAN CAUSE RETINAL DAMAGE. PART III, LINE 4B PROGRAM SERVICE ACCOMPLISHMENTS: PUBLIC HEALTH EDUCATION: DURING FY25, THE FOUNDATION CONTINUED TO PROVIDE EDUCATION AND SUPPORT TO PEOPLE AFFECTED BY RETINAL DEGENERATIVE DISEASES. THE FOUNDATION ALSO FIELDS A TEAM OF PROFESSIONALS FOCUSED ON EDUCATING OPHTHALMOLOGISTS AND OPTOMETRISTS ON THE LATEST ADVANCEMENTS WITH THE FOUNDATION'S RESOURCES AND RESEARCH ON THE INHERITED RETINAL DISEASE SPACE. TO KEEP OUR CONSTITUENTS AND PROFESSIONALS INFORMED, THE FOUNDATION PUBLISHES EXTENSIVE CONTENT VIA THE WEBSITE AND SOCIAL MEDIA/EMAIL CHANNELS; DISTRIBUTES A NEWSLETTER ONLINE AND IN PRINT; PRODUCES AND SHARES EDUCATIONAL PODCASTS WITH LEADING EXPERTS IN THE SPACE; HOSTS VIRTUAL AND IN-PERSON EDUCATIONAL AND NETWORKING SEMINARS; AND HOLDS QUARTERLY INSIGHTS FORUM CALLS TO INFORM THE COMMUNITY ABOUT SCIENTIFIC PROGRESS. THE CONTENT INCLUDES THE LATEST DEVELOPMENTS IN RESEARCH AND CLINICAL TRIALS, AS WELL AS PERSONAL STORIES FROM MEMBERS OF OUR COMMUNITY. ADDITIONALLY, THE FOUNDATION HOSTS REGIONAL FORUM PRESENTATIONS THAT PROVIDE TIMELY CONTENT TO EYE CARE PROFESSIONALS. CHAPTERS BRING THE FOUNDATION'S MESSAGE AND MISSION TO LIFE. IN FY25, THE FOUNDATION SUPPORTED OVER 47 VOLUNTEER-LED CHAPTERS IN 23 STATES IN THE US AND ONE CHAPTER IN LONDON, UK. OUR CHAPTERS HOST VISION CONNECTION, AN ENRICHING AND SUPPORTIVE GATHERING FOR THE BLIND AND LOW-VISION COMMUNITY. EACH SESSION COVERS EDUCATIONAL PRESENTATIONS, COMMUNITY ENGAGEMENT, FUNDRAISING, AND INTERACTIVE Q&A SESSIONS. PART III, LINE 4C PROGRAM SERVICE ACCOMPLISHMENTS: MY RETINA TRACKER REGISTRY: THE FOUNDATION MAINTAINS A RESEARCH DATABASE OF PEOPLE AND FAMILIES AFFECTED BY RARE INHERITED RETINAL DEGENERATIVE DISEASES. THE REGISTRY IS DESIGNED TO SHARE DE-IDENTIFIED INFORMATION ABOUT PEOPLE WITH AN INHERITED RETINAL DISEASE WITHIN THE IRD RESEARCH AND CLINICAL COMMUNITIES TO HELP ACCELERATE THE DISCOVERY OF TREATMENTS AND CURES. DURING FISCAL YEAR 2025, APPROXIMATELY 8,000 ADDITIONAL MEMBERS WERE ADDED TO THE REGISTRY, BRINGING THE TOTAL NUMBER OF REGISTERED INDIVIDUALS TO APPROXIMATELY 43,000. FORM 990, PART VI, SECTION A, LINE 2 JONATHAN STEINBERG AND JOSHUA STEINBERG HAVE A FAMILY RELATIONSHIP. FORM 990, PART VI, SECTION A, LINE 4 IN MARCH 2025, FFB AMENDED ITS BYLAWS TO ALIGN WITH THE CURRENT STRUCTURE AND OPERATING PRACTICES. NOTABLE CHANGES INCLUDE A REDUCTION IN THE NUMBER OF STANDING COMMITTEES, THE CREATION OF THE EXECUTIVE VICE CHAIR POSITION, REMOVAL OF THE PRESIDENT AS AN ELECTED OFFICER, AND THE INTRODUCTION OF TERM LIMITS. FORM 990, PART VI, SECTION A, LINE 6 MEMBERS OF FFB ARE KNOWN AS NATIONAL TRUSTEES. THE QUALIFICATIONS AND ELIGIBILITY FOR MEMBERSHIP AND THE MANNER OF ADMISSION INTO MEMBERSHIP IS PRESCRIBED BY RESOLUTION OF THE BOARD OF DIRECTORS. THE NATIONAL TRUSTEES ARE ENTITLED TO VOTE ON ELECTION OF DIRECTORS. FORM 990, PART VI, SECTION A, LINE 7A DURING THE ANNUAL MEETING OF THE NATIONAL TRUSTEES, MEMBERS OF THE BOARD OF DIRECTORS ARE ELECTED. FORM 990, PART VI, SECTION B, LINE 11B DATA TO PREPARE THE FEDERAL FORM 990 IS PROVIDED TO OUR OUTSIDE ACCOUNTING FIRM FOR PREPARATION AND GUIDANCE. AFTER IT HAS BEEN COMPLETED, A DRAFT OF THE FEDERAL FORM 990 IS REVIEWED BY THE VP, FINANCE AND CHIEF OPERATING OFFICER. WITH THE COO'S APPROVAL, THE DRAFT FEDERAL FORM 990 IS THEN MADE AVAILABLE TO ALL BOARD MEMBERS. ALL BOARD MEMBERS ARE INVITED TO ATTEND A SPECIAL MEETING OF THE FINANCE COMMITTEE TO REVIEW THE FEDERAL FORM 990. A FINAL DRAFT IS MADE AVAILABLE TO ALL BOARD MEMBERS BEFORE FILING. FORM 990, PART VI, SECTION B, LINE 12C IN CONNECTION WITH ANY ACTUAL OR POSSIBLE CONFLICT OF INTEREST, AN INTERESTED PERSON (INCLUDING OFFICERS, DIRECTORS, AND KEY EMPLOYEES) MUST DISCLOSE, IN WRITING PRIOR TO ANY DISCUSSION OR VOTE UPON A PROPOSAL, THE EXISTENCE AND NATURE OF HIS OR HER PERSONAL INTEREST TO THE CHAIR OF THE BOARD AND CHAIR OF THE BOARD COMMITTEE CONSIDERING THE PROPOSED TRANSACTION OR ARRANGEMENT. AFTER DISCLOSURE OF THE FINANCIAL OR NON-FINANCIAL INTEREST AND ALL MATERIAL FACTS, THE INTERESTED PERSON SHALL LEAVE THE BOARD OR COMMITTEE MEETING WHILE THE FINANCIAL OR NON-FINANCIAL INTEREST IS DISCUSSED AND VOTED UPON. THE REMAINING BOARD SHALL DECIDE IF A CONFLICT OF INTEREST EXISTS, AND IF SO, WHETHER THERE IS A COMPELLING REASON TO RECOMMEND TO THE BOARD THAT THE CONFLICT OF INTEREST POLICY BE OVERRIDDEN. A QUORUM IS NEEDED FOR VOTING AND THE VOTE TO OVERRIDE SHALL BE BY MAJORITY AND DULY NOTED IN THE MINUTES. FORM 990, PART VI, SECTION B, LINE 15 THE EXECUTIVE COMMITTEE (COMPRISED OF INDEPENDENT PERSONS) AND THE BOARD OF DIRECTORS APPROVES THE COMPENSATION OF THE CHIEF EXECUTIVE OFFICER. THE EXECUTIVE COMMITTEE APPROVES THE COMPENSATION OF THE OTHER CHIEF OFFICERS. ON A ROUTINE BASIS, EXTERNAL DATA PROVIDED BY OUTSIDE EXPERT COMPENSATION CONSULTANTS IS USED TO MEASURE REASONABLENESS OF SALARIES TO THE MARKET PLACE AND RESULTS ARE COMMUNICATED BY OUTSIDE CONSULTANTS TO THE BOARD CHAIR/COMPENSATION COMMITTEE. DECISIONS MADE BY THE COMMITTEE ARE CONTEMPORANEOUSLY DOCUMENTED. FORM 990, PART VI, SECTION C, LINE 19 FFB'S FEDERAL FORM 990 AND CONSOLIDATED AUDITED FINANCIAL STATEMENTS ARE AVAILABLE AT WWW.FIGHTBLINDNESS.ORG. OTHER PUBLIC DOCUMENTS INCLUDING THE CONFLICT OF INTEREST POLICY ARE AVAILABLE UPON REQUEST THROUGH THE CONTACT INFORMATION DISCLOSED ON FFB'S WEB SITE. THESE DOCUMENTS ARE AVAILABLE FOR THE SAME PERIOD OF DISCLOSURE AS SET FORTH IN SECTION 6104(D). FORM 990, PART VII, SECTION A: FFB ACTS AS THE COMMON PAYMASTER FOR THE FOUNDATION FIGHTING BLINDNESS RETINAL DEGENERATION FUND, A RELATED ORGANIZATION. BOARD MEMBERS WERE NOT COMPENSATED FOR THEIR SERVICE ON THE BOARD, WITH THE EXCEPTION OF THE CHAIR OF THE RD FUND BOARD, WHO WAS COMPENSATED IN ACCORDANCE WITH THE RD FUND BOARD'S APPROVED COMPENSATION POLICY. FORM 990, PART XI, LINE 9: REFUND OF PREVIOUSLY EXPENDED GRANTS 11,693. FOUNDATION FIGHTING BLINDNESS RETINAL DEGENERATION FUND 6925 OAKLAND MILLS ROAD 701 COLUMBIA MD 21045 450524687 FUNDS RESEARCH AND CLINICAL TRIALS TO FIND TREATMENTS FOR RETINAL DE 501(C)(3) LINE 12A, I FOUNDATION FIGHTING BLINDNESS INC 1 MACULAR DEGENERATION INTERNATIONAL INC 6925 OAKLAND MILLS ROAD 701 COLUMBIA MD 21045 363923922 FUNDRAISING IL 501(C)(3) LINE 7 FOUNDATION FIGHTING BLINDNESS INC 1 NATIONAL RETINITIS PIGMENTOSA FOUNDATION INC 6925 OAKLAND MILLS ROAD 701 COLUMBIA MD 21045 522072391 FUNDRAISING MD 501(C)(3) LINE 12A, I FOUNDATION FIGHTING BLINDNESS INC 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 FOUNDATION FIGHTING BLINDNESS RD FUND B 8771404 FAIR MARKET VALUE FOUNDATION FIGHTING BLINDNESS RD FUND O 1164027 FAIR MARKET VALUE PART II, IDENTIFICATION OF RELATED TAX-EXEMPT ORGANIZATIONS: NAME OF RELATED ORGANIZATION: FOUNDATION FIGHTING BLINDNESS RETINAL DEGENERATION FUND PRIMARY ACTIVITY: FUNDS RESEARCH AND CLINICAL TRIALS TO FIND TREATMENTS FOR RETINAL DISEASES